IsoRay Medical Inc.’s Proxcelan is a seed used in low dose radiation (LDR) permanent brachytherapy for prostate cancer. The reportedly fast-acting, high-energy medical isotope has demonstrated strong clinical results and is being heralded as the first leap forward in seed brachytherapy in 20 years.
According to IsoRay, Proxcelan offers advantages over other isotopes, delivering therapeutic radiation faster than other isotope seeds, Palladium-103 and Iodine-125, and at a reduced risk to patients when compared to surgery. Due to its characteristics, Proxcelan patients receive a higher initial dosage of radiation that attacks and kills cancer cells quickly, said the company. Its reportedly short half-life means that radiation leaves the body sooner than Iodine-125 and Palladium-103.